mRNA-1273
Phase 1Completed 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Conditions
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Trial Timeline
May 24, 2022 → Feb 27, 2026
NCT ID
NCT05397223About mRNA-1273
mRNA-1273 is a phase 1 stage product being developed by Moderna for SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus. The current trial status is completed. This product is registered under clinical trial identifier NCT05397223. Target conditions include SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus.
What happened to similar drugs?
4 of 20 similar drugs in SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus were approved
Approved (4) Terminated (1) Active (16)
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07266558 | Approved | Recruiting |
| NCT06113692 | Preclinical | Completed |
| NCT05894499 | Preclinical | Completed |
| NCT05894590 | Preclinical | Completed |
| NCT05894525 | Preclinical | Completed |
| NCT05397223 | Phase 1 | Completed |
| NCT05366322 | Preclinical | Completed |
| NCT04958304 | Preclinical | Terminated |
| NCT04958954 | Preclinical | Completed |
| NCT04860297 | Phase 3 | Completed |
| NCT04796896 | Phase 3 | Completed |
| NCT04649151 | Phase 3 | Completed |
| NCT04470427 | Phase 3 | Completed |
| NCT04405076 | Phase 2 | Completed |
Competing Products
20 competing products in SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1283 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1273.214 | Moderna | Phase 2 | 0 |
| SPIKEVAX | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| SPIKEVAX Bivalent | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 2 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273.211 | Moderna | Phase 3 | 0 |
| SPIKEVAX (mRNA-1273) | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |